Constellation Pharmaceuticals (NASDAQ:CNST) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The firm presently has a $7.75 target price on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 9.46% from the company’s current price.
According to Zacks, “Constellation Pharmaceuticals, Inc. operates as a bio-pharmaceutical company. It discovers and develops molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders. The company’s lead product candidates consists of CPI-1205, which inhibits enhancer of zeste homolog 2 and CPI-0610, which inhibits bromodomain and extra terminal domain. Constellation Pharmaceuticals, Inc. is based in Cambridge, United States. “
Other equities research analysts also recently issued reports about the company. Oppenheimer set a $21.00 price objective on Constellation Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 1st. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Constellation Pharmaceuticals in a research report on Friday, January 4th. Six equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $17.29.
Constellation Pharmaceuticals (NASDAQ:CNST) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14). On average, analysts predict that Constellation Pharmaceuticals will post -3.55 earnings per share for the current year.
A number of hedge funds have recently modified their holdings of CNST. TRV GP LLC purchased a new stake in Constellation Pharmaceuticals during the third quarter valued at approximately $20,419,000. Victory Capital Management Inc. purchased a new stake in shares of Constellation Pharmaceuticals in the third quarter worth approximately $957,000. BlackRock Inc. purchased a new stake in shares of Constellation Pharmaceuticals in the third quarter worth approximately $1,276,000. FMR LLC purchased a new stake in shares of Constellation Pharmaceuticals in the third quarter worth approximately $10,281,000. Finally, Dean Capital Investments Management LLC purchased a new stake in shares of Constellation Pharmaceuticals in the third quarter worth approximately $351,000. Institutional investors and hedge funds own 42.41% of the company’s stock.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
Featured Story: How the Consumer Price Index (CPI) is calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.